Pilot trial of chidamide, an oral histone deacetylase (HDAC) inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer.
机构：[1]Harbin Med Univ, Canc Hosp, Dept Med Oncol, Harbin, Heilongjiang, Peoples R China[2]Acad Mil Med Sci, Affiliated Hosp, Dept Breast Canc, Beijing, Peoples R China[3]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China河北医科大学第四医院[4]Shenzhen Chipscreen Biosci, Shenzhen, Peoples R China
第一作者机构：[1]Harbin Med Univ, Canc Hosp, Dept Med Oncol, Harbin, Heilongjiang, Peoples R China
推荐引用方式(GB/T 7714)：
Zhang Qingyuan,Wang Tao,Geng Cuizhi,et al.Pilot trial of chidamide, an oral histone deacetylase (HDAC) inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer.[J].JOURNAL OF CLINICAL ONCOLOGY.2017,35:doi:10.1200/JCO.2017.35.15_suppl.e12543.
APA：
Zhang, Qingyuan,Wang, Tao,Geng, Cuizhi,Zhang, Yue,Zhang, Jinwen...&Jiang, Zefei.(2017).Pilot trial of chidamide, an oral histone deacetylase (HDAC) inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer..JOURNAL OF CLINICAL ONCOLOGY,35,
MLA：
Zhang, Qingyuan,et al."Pilot trial of chidamide, an oral histone deacetylase (HDAC) inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer.".JOURNAL OF CLINICAL ONCOLOGY 35.(2017)
医学